Background {#Sec1}
==========

The prevention of cognitive decline and dementia is an increasingly important public health priority due to the growth of the global elderly population \[[@CR1]\]. The global prevalence of dementia has been rising, and the number of people with dementia is projected to total 81.1 million by 2040 \[[@CR2]\]. Dementia, the most severe cognitive disorder, not only negatively impacts the patients' quality of life but also creates a substantial burden for caregivers \[[@CR3], [@CR4]\].

Cognitive decline is a precursor to mild cognitive impairment (MCI) and is potentially the earliest clinical indicator of dementia \[[@CR5], [@CR6]\]. Most patients experience a subjective cognitive decline, also called subjective memory complaint, before noticeable cognitive impairment \[[@CR7], [@CR8]\]. Subjective Cognitive Decline (SCD) refers to a self-experienced persistent decline in cognitive abilities in comparison with a prior normal status and independent of the objective performance on neuropsychological tests \[[@CR9]\]. By definition, SCD is a sign of preclinical Alzheimer's disease and can occur before objective cognitive impairment appears. SCD can be diagnosed by several questionnaires of self-reported cognitive performance, such as the Mini Mental Status Examination (MMSE) and the Global Deterioration Scale (GDS) without the use of neuropsychological tests for objective assessment of cognitive function \[[@CR10]\]. Currently, there is no 'gold standard' measure for SCD \[[@CR11]\]. The international SCD Initiative Working Group has systematically identified 34 self-report SCD measures and has found wide variations in the definitions, cognitive domains, optimal items for each domain, item response options, and time frame across measures \[[@CR12], [@CR13]\].

SCD is a potential marker for future Mild Cognitive Impairment (MCI). Currently, MCI is diagnosed by one of three criteria: the revised Mayo Clinic Criteria, the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), or the National Institute on Aging-Alzheimer's Association workgroup (NIA-AA) \[[@CR14]\]. Among the three diagnostic criteria, one commonly shared core characteristic is the objective evidence of impairment from standardized neuropsychological tests in ≥1 cognitive domains (i.e., memory, executive function, attention, language, and visuospatial skills) \[[@CR14]\]. Although there is no gold standard regarding neuropsychological tests, it is critical to investigate all major cognitive domains for objective cognitive impairment. Dementia \[[@CR15]\], including Alzheimer's disease and vascular dementia, can be detected by objective measures of cognitive impairment and biomarkers, such as β-amyloid (1--42), total tau, and phospho-tau-181 in cerebrospinal fluid \[[@CR16]\].

Milk and dairy products are recommended by many dietary guidelines for meeting the daily requirements for calcium, protein, and vitamin B12 intake. These nutrients are important for maintaining good health in older adults. The biological mechanisms linking milk or dairy consumption to cognitive function are not fully understood. It has been postulated that phospholipids in the milk fat globule membrane (MFGM) might affect cognitive function \[[@CR17]\]. There are several possible reasons for why the intake of MFGM could benefit cognitive function \[[@CR18]\]. First, MFGM contains high levels of choline derivatives (i.e., phosphocholine, glycerophosphocholine, phosphatidylcholine and sphingomyelin) \[[@CR19]\]. These compounds may play an important role in the development of the nervous system. Second, sphingomyelin metabolites are essential elements of the myelin sheath that covers the axons of neurons. Therefore, sphingomyelin metabolites support the myelination and production of neurotransmitters in the brain. Additionally, previous studies have suggested that dietary phospholipids are effective transporters of essential fatty acids that could improve brain health by lowering endoplasmic reticulum stress \[[@CR20]\], which is known to increase the risk of neurodegenerative disorders such as Alzheimer's disease. Lastly, the solubility of phospholipids in brain cell membranes may enhance the neuroplasticity of the hippocampus and support dopamine and glutamate transmission \[[@CR19]\].

A previous meta-analysis that examined the potential relationship between milk consumption (with or without other dairy products) and cognitive function or disorders showed that the highest level of milk intake compared to the lowest intake level (as defined by the original studies) was significantly associated with a lower risk of cognitive disorders (pooled odds ratio \[OR\] = 0.72; 95% CI: 0.56--0.93; *I*^*2*^ = 64%) \[[@CR21]\]. However, this meta-analysis pooled cohort studies and cross-sectional studies together and did not consider the risk-of-bias across the studies included in the meta-analysis as per the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guideline \[[@CR22]\]. A risk-of-bias assessment can help explain variation (heterogeneity) in the results of studies included in a systematic review or meta-analysis, in that more rigorous studies are more likely to yield results that are closer to the truth. The potential limitations of the included studies must be carefully considered in the evidence synthesis in order to obtain reliable conclusions. Therefore, we conducted a systematic review and meta-analysis following the rigorous methods outlined in the Cochrane handbook for systematic reviews to evaluate whether there is a causal relationship between milk intake and cognitive function or dementia.

Methods {#Sec2}
=======

Identification of studies and study eligibility criteria {#Sec3}
--------------------------------------------------------

The search strategy was developed based on the search strategy used in an earlier meta-analysis by Wu and Sun \[[@CR21]\]. The searches were carried out in 3 databases: PubMed (from inception to September 18, 2017), CINAHL (from inception to October 12, 2017) and EMBASE (from inception to October 12, 2017) and were limited to human studies without language restrictions. The complete search strategy is presented in Additional file [1](#MOESM1){ref-type="media"}: Table S1. In addition to the citations identified in our searches, all studies included in Wu and Sun's meta-analysis were also evaluated based on the eligibility criteria of the present study.

For the present systematic review, prospective cohort studies and intervention trials with follow-up durations of longer than 4 weeks in adults, aged 18 years or older, were included. To be included, studies must have compared varying doses of milk intake, alone or in combination with other dairy products (i.e., yogurt and cheese), and reported outcomes related to cognitive function, including any stage of dementia (i.e., cognitive decline, mild cognitive impairments, and dementia) or any type of dementia (i.e., Alzheimer's disease and vascular dementia). Studies including schizophrenic patients or those that measured only isolated specific nutrients in milk were excluded.

Study selection process {#Sec4}
-----------------------

All citations identified from the literature searches were independently screened by at least two investigators, according to the pre-established screening criteria to exclude irrelevant abstracts (e.g., animal, in vitro, and cross-sectional studies). The abstract screening was performed using an open-source, online software---Abstrackr \[[@CR23]\]. Full-text screening was independently executed by two investigators based on the final study eligibility criteria. Conflicts regarding both the abstract and full-text screenings were resolved by group consensus.

Data extraction, and quality assessment {#Sec5}
---------------------------------------

Two independent investigators extracted data from each included study using the standardized data extraction forms. Discrepancies were resolved between the two investigators. The risk of bias (i.e., quality) of each included study was assessed using validated tools. For prospective cohort studies, we adapted the Newcastle Ottawa Scale (NOS) \[[@CR24]\]. The modified NOS tool included quality items regarding potential selection bias, comparability of the comparison groups (e.g., potential for confounding bias), adequate sample size (e.g., power calculation), and potential biases in outcome assessments and selective outcome reporting. The response options for each quality item were high, unclear, or low risk, with detailed instructions on how to reach these judgements (Additional file [1](#MOESM1){ref-type="media"}: Table S2). When five or more items were rated as having a high or unclear risk, the overall risk of bias (ROB) was rated as high. When less than two of the quality items were rated as having a high or unclear risk, the overall ROB was rated as low. These cutoffs for rating the overall ROB were arbitrary, as the NOS did not provide guidance for overall ROB rating. For intervention trials, we used the revised Cochrane risk-of-bias tool for the specific intervention trial designs \[[@CR25]\]. This ROB tool includes quality items regarding potential bias arising from the randomization process, bias due to deviations from the intended intervention, bias due to missing outcome data, bias in outcome measurement, and bias in selective outcome reporting. The suggested algorithms for reaching ROB judgments, as specified in the tool manual, were followed \[[@CR25]\].

Qualitative synthesis {#Sec6}
---------------------

All the included studies were qualitatively synthesized in narrative form and in summary tables that tabulated the key features of the study populations, study designs, interventions or exposures, outcomes, and results. The strength of evidence (SoE) for major comparisons and outcomes was assessed through a consensus process of the entire research team, using an evidence grading system utilized by the American Diabetes Association and other prominent groups \[[@CR26], [@CR27]\]. Briefly, for each outcome, the SoE level was rated as A (Strong), B (Moderate), C (Limited), D (Inadequate), E (Expert Consensus or Clinical Experience), or NA (Not Applicable). Further details can be found in Additional file [1](#MOESM1){ref-type="media"}: Table S3.

Quantitative synthesis {#Sec7}
----------------------

In light of large clinical heterogeneity (e.g., different outcome measures and various milk intake exposures), a random-effects meta-analysis was performed when there were at least three unique studies that reported sufficient quantitative data for the same outcome \[[@CR28]\]. After careful examination of all the extracted quantitative data and heterogeneity issues, only prospective cohort studies reporting the associations between milk intake and cognitive decline outcomes could be pooled. Further, a meta-analysis comparing only the highest and the lowest milk intake level was conducted, because data were insufficient to conduct a dose-response meta-regression. Both the Q statistic (considered significant when the *P* value was less than 0.10) and the *I*^*2*^ index were used to quantify the extent of statistical heterogeneity \[[@CR29]\]. *I*^*2*^ values of 25%, 50% and 75% were defined as low, moderate and high heterogeneity, respectively. However, these cutoffs are arbitrary and were used for descriptive purposes only \[[@CR30]\]. All calculations and meta-analyses were conducted in Stata SE 14 (Stata Corp). The analytical dataset can be found in the Additional file [2](#MOESM2){ref-type="media"}. Two-tailed *P* values less than 0.05 were considered significant.

Results {#Sec8}
=======

Our literature search yielded a total of 2407 citations. Of these, 1777 unduplicated abstracts were identified for the dual abstract screening. Further, we screened 29 potentially relevant full-text articles and finally included 8 articles (1 RCT and 7 prospective cohort studies). Figure [1](#Fig1){ref-type="fig"} summarizes the details of the literature search and selection process. The characteristics of the included studies are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. In this paper, we organized results by research questions, namely the effects of milk intake on cognitive function, cognitive decline/impairment, and dementia. One RCT examined only cognitive function outcomes, and the results of this RCT were summarized first, before the results of cohort studies.Fig. 1Literature search and study selection processTable 1Characteristics of the included RCT studies^a^Author, Year\
\[Reference\]CountryDurationMale (%)Baseline Age (years)Number of ParticipantsInterventionOutcome MeasuresROB assessmentsTypeMethod of AssessmentCrichton, 2012 \[[@CR31]\]South Australia and Canada6 months28.951.638Four servings of reduce fat dairy/day vs. one serving of reduced fat diary/daya. Verbal memory\
b. Processing speed\
c. Working memory\
d. Visual attention\
e. Verbal fluency\
f. Abstract reasoning\
g. Selective attention\
h. Executive function\
i. Psychological well-beinga. RAVLT total, RAVLT delayed verbal recall, RAVLT written recall\
b. Digit symbol coding, inspection time\
c. Spatial Span forward, Spatial Span backward, Spatial Span total, Letter Number Sequencing\
d. Letter cancellation\
e. Initial letter fluency\
f. Matric reasoning\
g. Stroop interference\
h. Design fluency total\
i. DASS total• Bias arising from the randomization process: Some concerns\
• Bias due to deviations from intended interventions: Some concerns\
• Bias due to missing outcome data: High ROB\
• Bias in measurement of the outcome: Some concerns\
• Bias in the selection of the reported results: Low ROB\
• Overall ROB: Moderate (= Some concerns)^a^ *DASS* The Depression Anxiety Stress Scale, *NA* not applicable, *NR* not reported, *RAVLT* the Rey Auditory Verbal Learning TestTable 2Characteristics of the included cohort studies^a^Author, Year \[Reference\]\
Cohort nameCountryFollow-Up (years)Male (%)Baseline Age (years) (mean)Health StatusNumber of ParticipantsExposureOutcomeAdjustmentTypeMethod of EasementCategoryTypeMethod of AssessmentNutrientsDemographicsMedicationLife styleAlmeida, 2006 \[[@CR36]\], NRAustralia4.8100Impaired cognitive function: 77.3; preserved cognitive function: 77.6Generally healthy601Consumed full-cream milk regularlySelf-reported questionnaireDichotomous: Regular vs. RareCognitive functionMMSE, GDS-15XXAraki, 2017 \[[@CR35]\], Follow up for the J-EDIT trialJapan642.62NRDiabetes mellitus237Dairy productsYoshimura et al.'s validated FFQTertiles of dairy intake (g/d):\
≤ 133.9, 134--197.9, ≥ 197Cognitive functionMMSEXXKesse-Guyot, 2016 \[[@CR32]\], the SU.VI.MAX 2 observational follow-up studyFrance5^b^5253.7Generally healthy3076a. Total dairy products;\
b. Milk only24-h dietary recordsTertiles of dairy intake (g/d):\
\<  191.6, 191.6--327.2, \>  327.2Cognitive functionTMT, RI-48 testXXXXOzawa, 2014 \[[@CR38]\], The Hisayama StudyJapan1742.3Q1: 68.6; Q2: 69.8; Q3: 68.9; Q4: 70.4Generally healthy1081Milk and dairy consumptiona 70-item semi quantitative FFQQuintiles (g/d):\
Male - \<  45, 45--96, 97--197, ≥ 198;\
Female - \< 20, 20--75, 76--173, ≥ 174All-cause Dementia, AD, VaDDSMXXXXPetruski-Ivleva, 2017 \[[@CR33]\], The Atherosclerosis Risk in Communities (ARIC) cohortUS2044Milk intake almost never: 56.7; milk intake \< 1 glass/day: 57.2; milk intake 1 glass/day: 58.5; milk intake \> 1 glass/day: 57.9Generally healthy13,752Milk IntakeFFQAlmost never,\
\<  1 glass/day,\
1 glass/day,\
\>  1 glass/dayCognitive functionDWRT, DSST, WFTXXXXVercambre, 2009 \[[@CR34]\], E3N (Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale) subcohortFrance13065.5Generally healthy4758Milk and yogurtan extensive diet history questionnaire covering daily consumption of 208 foods and beveragesTertiles (no dose for each tertile)Cognitive declineDECO score, 4-IADL scoreXXXXYamada, 2003 \[[@CR37]\], Adult Health Study follow-up studyJapan22^b^26.8NRGenerally healthy1774Milk intakeself-administered questionnaire between 1965 and 1968Daily vs. \<  4 times a weekAD, VaDDSM-IVXXXX^a^*AD* Alzheimer's disease, *DECO* observed cognitive deterioration, *DSM* the Diagnostic and Statistical Manual, *DSST* the Digit Symbol Substitution Test, *DWRT* the Delayed Word Recall Test, *FFQ* Food Frequency Questionnaire, *GDS-15* Geriatric Depression Scale 15, *IADL* instrumental activities of daily living, *MMSE* Mini-Mental State Examination, *NR* not reported, *TMT* the Delis-Kaplan trail-making test, *VaD* vascular dementia, *WFT* the Word Fluency Test^b^Follow-up time is calculated based on the first year of cognitive assessment minus the last year of baseline information assessment, since the data are not reported in the original paper

Milk and dairy intake and cognitive function {#Sec9}
--------------------------------------------

### RCTs {#Sec10}

Only one crossover RCT \[[@CR31]\] met the inclusion criteria (Table [1](#Tab1){ref-type="table"}). Participants (*n* = 38) were randomized to either a high-dairy diet (four servings of reduced-fat dairy foods per day) or the low-dairy diet (one serving of reduced-fat dairy foods per day) for 6 months, followed by an alternate diet switch for another 6 months, without a washout period. Nine indicators were used to measure cognitive performance: 1) verbal memory, 2) processing speed, 3) working memory, 4) visual attention, 5) verbal fluency, 6) abstract reasoning, 7) selective reasoning, 8) executive function, and 9) psychological well-being. Among these cognitive function outcomes, only backward spatial span in working memory showed a significant difference between the high-dairy and low-dairy diet groups (mean ± SEM; 7.9 ± 0.4 vs. 7.3 ± 0.4, *P* = 0.046 \[[@CR31]\]) (Table [1](#Tab1){ref-type="table"}). The overall ROB of this crossover RCT was rated as moderate due to the high risk for selective outcome reporting bias, some concerns regarding bias due to deviations from intended interventions and bias in outcome measurements, and no information regarding the randomization process (Table [4](#Tab4){ref-type="table"}).

### Cohort studies {#Sec11}

Two cohort studies \[[@CR32], [@CR33]\] investigated the associations between milk or dairy intake and cognitive functions among older male and female adults after 5 to 20 years of follow-up in France and in the U.S. (Table [2](#Tab2){ref-type="table"}). One cohort study assessed milk intake using a food-frequency questionnaire (FFQ) \[[@CR33]\], and the other evaluated total dairy and milk intake using a 24-h recall \[[@CR32]\]. The two cohort studies utilized the following assessment tools to assess cognitive function: DWRT (Delayed Word Recall Test), DSST (Digital Symbol Substitution Test), WFT (Word Fluency Test), RI-48 test, and the Delis-KapLan Trail Making Test. Both studies showed mixed results regarding the associations between milk intake and a variety of cognitive function outcomes. Specifically, the first cohort study showed no significant association between total dairy intake and cognitive function (i.e., working memory and verbal memory \[[@CR32]\]). This study indicated no significant association between milk intake and working memory, while a higher milk intake was associated with poorer verbal memory performance \[[@CR32]\]. The other study showed no significant association between milk intake and verbal learning, short-term memory, executive function or expressive language but found that a higher milk intake was significantly negatively associated with executive function \[[@CR33]\] (Table [3](#Tab3){ref-type="table"}). The overall ROB was rated as moderate for both studies, primarily due to inadequate methods used to ascertain exposure, unclear risk for statistical power and high risk for biased outcome assessment methods (Table [4](#Tab4){ref-type="table"}).Table 3Results of the prospective cohort studies^a^Study\
\[Reference\]OutcomeOutcome DefinitionTotal *N*No. of EventsEvent Rate (%)IntakeIntake CategoryAmountMetricEstimateLower CIUpper CI*P*-valueKesse-Guyot, 2016 \[[@CR32]\]Working memoryForward and backward digit span tests and log-transformed TMT score3076NANATotal dairy productsLow\<  191.6 g/dmean differencerefrefref0.33Medium191.6--327.2 g/dmean difference0.68−0.161.52High\>  327.2 g/dmean difference0.43−0.431.29Verbal memory3 tests including two verbal fluency tasks and RI-48 cued recall task3076NANATotal dairy productsLow\<  191.6 g/dmean differencerefrefref0.51Medium191.6--327.2mean difference0.05−0.780.89High\>  327.2mean difference−0.29−1.150.57Petruski-Ivleva, 2017 \[[@CR33]\]Verbal learning and short-term memoryDWRT z13,752NANAMilk intakeAlmost neverNRmean differencerefrefrefNR\<  1 glass/dayNRmean difference−0.04−0.130.061 glass/dayNRmean difference−0.03−0.140.08\>  1 glass/dayNRmean difference−0.1−0.20Executive functionDSST z13,752NANAMilk intakeAlmost neverNRmean differencerefrefrefNR\<  1 glass/dayNRmean difference−0.04−0.0901 glass/dayNRmean difference−0.07−0.12− 0.01\>  1 glass/dayNRmean difference−0.09−0.14−0.03Executive function and expressive languageWFT z13,752NANAMilk intakeAlmost neverNRmean differencerefrefrefNR\<  1 glass/dayNRmean difference−0.04−0.090.021 glass/dayNRmean difference−0.02− 0.080.05\>  1 glass/dayNRmean difference−0.05−0.110.01CognitionGlobal z13,752NANAMilk intakeAlmost neverNRmean differencerefrefrefNR\<  1 glass/dayNRmean difference−0.05−0.110.021 glass/dayNRmean difference−0.06−0.130.02\>  1 glass/dayNRmean difference−0.1−0.16−0.03Almeida, 2006 \[[@CR36]\]Successful mental health agingMMSE ≥24 and GDS-15 \< 560114424.0%Full-cream milkRareNRHRrefrefrefNRRegularlyNRHR0.630.450.89Araki, 2017 \[[@CR35]\]Cognitive declineDecline in MMSE ≥21013332.7%Dairy productsTertile 1≤ 133.9HR2.80.7410.8Tertile 2134--196.9HR3.60.8815Tertile 3≥ 197HRrefrefref\>  0.05Vercambre, 2009 \[[@CR34]\]Recent cognitive declineDECO \< 33475851810.9%Milk and yogurtTertile 1NRORrefrefref0.182Tertile 2NROR1.210.971.5Tertile 3NROR1.170.931.46Functional impairment4-IADL\> 0475871615.0%Milk and yogurtTertile 1NRORrefrefref0.799Tertile 2NROR1.040.851.26Tertile 3NROR0.970.791.2Yamada, 2003 \[[@CR37]\]Vascular DementiaDSM-IV1774382.1%Milk intakeless than twice a weekNRORrefrefref2--4 times a weekNROR0.418NRNR0.107dailyNROR0.257NRNR0.002Alzheimer's DiseaseDSM-IV1774512.9%Milk intakeless than twice a weekNRORrefrefref2--4 times a weekNROR0.741NRNR0.485dailyNROR0.633NRNR0.145Vascular DementiaDSM-IV1774382.1%Milk intake\<  4 times a weekNRORrefrefref0.014almost dailyNROR0.350.140.77Ozawa, 2014 \[[@CR38]\]All-cause dementiaDSM-III108130328.0%Milk and Dairy ConsumptionQuartile 1women \< 45 g/d; men \< 20 g/dHRrefrefref0.09Quartile 2women 45--96 g/d; men 20--75 g/dHR0.850.621.18Quartile 3women 97--197 g/d; men 76--173 g/dHR0.690.50.96Quartile 4women ≥198 g/d; men ≥174 g/dHR0.80.571.11Alzheimer's DiseaseDSM-III108116615.4%Milk and Dairy ConsumptionQuartile 1women \< 45 g/d; men \< 20 g/dHRrefrefref0.03Quartile 2women 45--96 g/d; men 20--75 g/dHR0.640.410.99Quartile 3women 97--197 g/d; men 76--173 g/dHR0.570.370.87Quartile 4women ≥198 g/d; men ≥174 g/dHR0.630.410.98Vascular DementiaDSM-III1081989.1%Milk and Dairy ConsumptionQuartile 1women \< 45 g/d; men \< 20 g/dHRrefrefref0.14Quartile 2women 45--96 g/d; men 20--75 g/dHR1.020.591.77Quartile 3women 97--197 g/d; men 76--173 g/dHR0.740.421.33Quartile 4women ≥198 g/d; men ≥174 g/dHR0.690.371.29^a^ *DECO* observed cognitive deterioration, *DSM* the Diagnostic and Statistical Manual, *DSST* the Digit Symbol Substitution Test, *DWRT* the Delayed Word Recall Test, *GDS-15* Geriatric Depression Scale 15, *IADL* instrumental activities of daily living, *MMSE* Mini-Mental State Examination, *NA* not applicable, *NR* not reported, *ref*. reference, *WFT* the Word Fluency TestTable 4Risk of bias assessment for the included cohort studies^a^Author, YearRepresentativeness of the exposed cohortSelection of the non-exposed cohortAscertainment of the nutrient's exposureOutcome of interest absent at baselineControl for important confoundersAdequate sample size and powerOutcome assessmentCompleteness of cohort follow-upSelective Outcome ReportingOverall ROBAlmeida, 2006 \[[@CR36]\]HighLowHighHighLowLowHighHighLowHighAraki, 2017 \[[@CR35]\]HighLowHighLowLowUnclearHighLowLowModerateKesse-Guyot, 2016 \[[@CR32]\]HighLowLowHighLowUnclearHighLowLowModerateOzawa, 2014 \[[@CR38]\]LowLowLowLowLowUnclearLowLowLowLowPetruski-Ivleva, 2017 \[[@CR33]\]LowLowHighLowLowUnclearHighLowLowModerateVercambre, 2009 \[[@CR34]\]HighLowHighHighLowUnclearHighHighLowHighYamada, 2003 \[[@CR37]\]HighLowHighHighLowUnclearLowLowLowModerate^a^Detailed instructions of the modified NOS tool are presented in Additional file [1](#MOESM1){ref-type="media"}: Table S2

Milk and dairy intake and cognitive decline or impairment {#Sec12}
---------------------------------------------------------

Three cohort studies \[[@CR34]--[@CR36]\] reported the associations between milk or dairy intake and cognitive decline or cognitive impairment among elderly participants after 4.8 to 13 years of follow-up (Table [2](#Tab2){ref-type="table"}). Milk or dairy intake was assessed by FFQ or diet history questionnaire. One of these studies compared a 'regular' consumption group with a 'rare' consumption group of full-cream milk \[[@CR36]\], while the other two studies investigated the associations between cognitive decline/impairments and tertiles of milk intake \[[@CR34], [@CR35]\]. Cognitive impairment or decline was assessed using the MMSE (Mini-Mental State Examination), DECO ('DEtérioration Cognitive Observée', observed cognitive deterioration) and IADL (Iinstrumental Activities of Daily Living). One cohort study found that the regular full-cream milk consumption group demonstrated a significant decrease in successful mental health aging compared with the rare consumption group (adjusted hazard ratio = 0.63; 95% CI: 0.45, 0.89) \[[@CR36]\]. The other two studies found no significant associations between milk and dairy consumption and cognitive decline \[[@CR34], [@CR35]\] (Table [3](#Tab3){ref-type="table"}). Our random-effects meta-analysis results did not show significant differences in risk for cognitive decline or cognitive impairment by comparing the highest milk intake to lowest intake groups (pooled adjusted risk ratio = 1.21; 95% CI: 0.81, 1.82), with large statistical heterogeneity (*I*^*2*^ = 64.1%) (Fig. [2](#Fig2){ref-type="fig"}). Overall, the ROB was rated as being moderate or high, mainly due to high loss of follow-up (\> 20%) and inadequate methods used to ascertain exposure (Table [4](#Tab4){ref-type="table"}).Fig. 2Summary associations between milk intake and cognitive decline

Milk and dairy intake and Alzheimer's disease {#Sec13}
---------------------------------------------

Two cohort studies \[[@CR37], [@CR38]\] examined the associations between milk or dairy intake and Alzheimer's disease among elderly participants \[[@CR38]\] and adult men and women \[[@CR37]\] after 17 and 22 years of follow-up. Milk or dairy intake was assessed using an FFQ, and Alzheimer's disease was assessed by DSM (Diagnostic and Statistical Manual of Mental Disorders) in both studies (Table [2](#Tab2){ref-type="table"}). The results of these two studies were inconsistent. One study showed that consuming milk less than twice a week was not significantly associated with the risk of developing Alzheimer's disease, compared with daily or 2 to 4 times a week milk intake \[[@CR37]\]. Overall, the ROB of this study was rated as being moderate, primarily due to concerns about the representativeness of the study population and inadequate methods used to ascertain exposure (Table [4](#Tab4){ref-type="table"}). The other study reported that higher milk and dairy intake significantly reduced the risk of Alzheimer's disease (*P* for trend = 0.03 \[[@CR38]\]) (Table [3](#Tab3){ref-type="table"}). Overall, the ROB of this study was rated as being low (Table [4](#Tab4){ref-type="table"}).

Milk and dairy intake and vascular dementia {#Sec14}
-------------------------------------------

Two cohort studies assessed the relationship between milk or dairy intake and vascular dementia, assessed by DSM \[[@CR37], [@CR38]\]. The characteristics of these two cohorts were described earlier (Table [2](#Tab2){ref-type="table"}). Similar to Alzheimer's disease outcomes, these two studies showed inconsistent results for vascular dementia outcomes. Specifically, the first study reported that the almost daily milk intake group (vs. \< 4 times a week of milk intake group) had a significantly reduced risk of vascular dementia \[[@CR37]\], while the second study showed nonsignificant associations between quartiles of milk and dairy intake and risk of vascular dementia \[[@CR38]\]. Overall, the ROB of the two studies was rated as being low and moderate, as described earlier (Table [4](#Tab4){ref-type="table"}).

Milk and dairy intake and all-cause dementia {#Sec15}
--------------------------------------------

One cohort study assessed the association between milk and dairy intake and all-cause dementia, assessed by DSM III, after 17 years of follow-up \[[@CR38]\]. The characteristics of this study were described earlier (Table [2](#Tab2){ref-type="table"}). The results showed no significant associations between quartiles of milk and dairy intake and risk for developing all-cause dementia (Table [3](#Tab3){ref-type="table"}). Overall, the ROB of this study was rated as being low (Table [4](#Tab4){ref-type="table"}).

Overall strength of evidence (SoE) {#Sec16}
----------------------------------

We graded the overall SoE as being inadequate for the causal relationships between milk consumption and cognitive decline/impairment, all-cause/vascular dementia, and Alzheimer's disease (Table [5](#Tab5){ref-type="table"}).Table 5SoE grading: higher vs. lower milk intake by outcome^a^OutcomeStudies, n (reference)RCTsCohort studiesSoE gradeExplanationCognitive function1 \[[@CR31]\]2 \[[@CR32], [@CR33]\]InadequateOnly 1 RCT was rated as having a moderate ROB; Cohort studies were rated as having a moderate to high ROBCognitive decline/impairmentsn/a3 \[[@CR34]--[@CR36]\]InadequateNo RCT; Cohort studies were rated as having a moderate to high ROB. Large heterogeneity in the meta-analysis.All-cause dementian/a1 \[[@CR38]\]InadequateOnly 1 cohort study that was rated as having a low ROBAlzheimer's diseasen/a2 \[[@CR37], [@CR38]\]InadequateCohort studies that were rated as having a low to moderate ROB showed inconsistent findingsVascular dementian/a2 \[[@CR37], [@CR38]\]InadequateTwo cohort studies that were rated as having a low to moderate ROB showed inconsistent findings^a^The SoE grading scheme is presented in Additional file [1](#MOESM1){ref-type="media"}: Table S3

Discussion {#Sec17}
==========

This systematic review revealed that the current evidence (7 cohort studies and 1 RCT) is inadequate to draw a conclusion for the causal relationship between milk or dairy intake and cognitive decline or disorders in older adults. The included cohort studies showed large clinical and methodological heterogeneity, hampering the comparability of the study findings. Specifically, milk or dairy intake assessments were heterogeneous, in that studies used various instruments to measure intake (e.g., food frequency questionnaires \[FFQ\], 24-h recall, or diet history questionnaires) and definitions of milk intake. The types of milk were also variably defined across studies, such as full-cream milk, dairy products, milk and dairy, or fat-reduced dairy foods. Most cohort studies were conducted in generally healthy populations \[[@CR32]--[@CR34], [@CR36]--[@CR38]\], except for one \[[@CR35]\] that was conducted among individuals with diabetes. Moreover, the included cohort studies utilized a variety of assessment tools to diagnose age-related cognitive disorders and adjusted for different sets of confounding factors in the statistical analyses.

The strength of this systematic review is that we followed the highest methodological standards for evidence synthesis and employed strict inclusion criteria regarding the study designs, which can better determine a causal inference. The previous meta-analysis included cross-sectional studies and did not consider risk-of-bias in their analyses or in drawing their conclusions \[[@CR21]\]. Because cross-sectional studies cannot assess the temporality between milk intake and cognitive function, we selected only prospective cohort studies and intervention studies for this systematic review. However, our meta-analysis is limited because of the concerns of risk-of-bias in the included cohort studies (e.g., potential residual confounding) and imprecise measurements of milk intake due to the limitations of FFQs for assessing dietary exposures in observational studies. Additionally, our meta-analysis was based on extreme quantile (highest vs. lowest quintile/quartile) comparisons, which has very limited interpretability, because the definitions of intake levels varied across studies. The variations in exposure levels may explain the large statistical heterogeneity (*I*^*2*^ = 64%; *P* = 0.06) in the meta-analysis, but we could not conduct a dose-response meta-analysis due to insufficient quantitative data to estimate and standardized the 'doses' of milk intake levels.

In light of the limitations in this body of evidence, we have a few suggestions for future research. First, the use of biomarkers would overcome the limitations of self-reported dietary assessments. These self-reported dietary assessments are prone to measurement errors due to recall bias, under/over-reporting, and incompleteness of the food composition database \[[@CR39], [@CR40]\]. Because self-reported dietary measures rely heavily on the responders' recall, recall bias is a particularly important issue in the study of cognitive function. Mild cognitive impairment has shown to attenuate the validity of FFQs when comparing to biomarkers of nutrient intake \[[@CR41], [@CR42]\]. Poor cognitive ability was associated with suspected recall errors on the FFQ \[[@CR43]\]. As an objective complementary tool for dietary assessment, milk intake biomarkers, such as adipose tissue and circulating levels of pentadecanoic acid (C15:0) \[[@CR44]\], would be very useful. Second, there is an urgent need to develop validated, standardized tests of cognitive impairment and dementia to make the research outcomes comparable and able to be quantitatively combined. We found substantial heterogeneity in the assessment tools across the included studies and poor descriptions of outcome measures. Each outcome measure for cognitive impairment and dementia exclusively assessed cognition, function, and other domains (e.g., quality of life, mood, and behavior) or a combination of these domains \[[@CR45]\]. To increase the usefulness of SCD measures, the international SCD Initiative Working Group issued a call for international collaboration to promote the harmonization and pooling of cognitive self-reported data and greater consistency in the measurement of cognitive decline \[[@CR12]\]. The working group had agreed to a common framework and research procedures to study the role of SCD as a marker of preclinical Alzheimer's disease \[[@CR9]\]. Specifically, there is a need to derive a small number of well-constructed, easy-to-administer items with adequate reliability across diverse samples of older adults. In summary, future research could be improved through the use of milk intake biomarkers and standardized assessment tools for cognitive function to strengthen causal inferences.

Conclusions {#Sec18}
===========

Based on best available evidence, we concluded that the overall strength of evidence is inadequate for the effects of milk or dairy consumption on cognitive decline and disorders, due to the insufficient number of high-quality studies and large heterogeneity across studies. To draw a firm conclusion, high quality RCTs with sufficient sample sizes, use of milk intake biomarkers, and standardized assessment tools for cognitive function are needed to identify the role of milk or dairy intake in cognitive function among older adults.
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DECO

:   'DEtérioration Cognitive Observée' (observed cognitive deterioration)

DSM

:   Diagnostic and Statistical Manual of Mental Disorders

DSST

:   Digital Symbol Substitution Test

DWRT

:   Delayed Word Recall Test

FFQ

:   Food frequency questionnaire

GDS

:   Global Deterioration Scale

IADL

:   Instrumental Activities of Daily Living

MCI

:   Mild cognitive impairment

MFGM

:   Milk fat globule membrane

MMSE

:   Mini Mental Status Examination

MMSE

:   Mini-Mental State Examination

NIA-AA

:   National Institute on Aging-Alzheimer's Association workgroup

NOS

:   Newcastle Ottawa Scale

PRISMA

:   Preferred reporting items for systematic reviews and meta-analyses

RCT

:   Randomized controlled trial

ROB

:   Risk of bias

SCD

:   Subjective Cognitive Decline

SoE

:   Strength of evidence

WFT

:   Word Fluency Test
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